Title | Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia |
Authors | Xu, Zheng-Li Huang, Xiao-Jun Liu, Kai-Yan Chen, Huan Zhang, Xiao-Hui Han, Wei Chen, Yu-Hong Wang, Feng-Rong Wang, Jing-Zhi Wang, Yu Chen, Yao Yan, Chen-Hua Xu, Lan-Ping |
Affiliation | Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Peoples Hosp, Inst Hematol, Beijing, Peoples R China. Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China. Peking Univ, Peoples Hosp, Dept Hematol, Inst Hematol,Beijing Key Lab Hematopoiet Stem Cel, 11 Xizhimen South St, Beijing 100044, Peoples R China. |
Keywords | allogeneic stem cell transplantation pediatric T-cell acute lymphoblastic leukaemia VERSUS-HOST-DISEASE BONE-MARROW-TRANSPLANTATION CHILDRENS ONCOLOGY GROUP 1ST COMPLETE REMISSION 2ND REMISSION HEMATOLOGICAL MALIGNANCIES ANTITHYMOCYTE GLOBULIN MYELOID-LEUKEMIA RESIDUAL DISEASE CHEMOTHERAPY |
Issue Date | 2016 |
Publisher | PEDIATRIC TRANSPLANTATION |
Citation | PEDIATRIC TRANSPLANTATION.2016,20(4),572-580. |
Abstract | Paediatric HR T-cell ALL demonstrates dismal prognosis with chemotherapy, and poor outcomes could be improved with allo-SCT. HID-SCT is an almost immediately available choice; however, few studies have focused on the outcomes of HID-SCT for paediatric HR T-ALL. Forty-eight consecutive HR T-ALL children who underwent HID-SCT were included. Survival outcomes and factors predictive of outcomes were retrospectively analysed. Of the 48 patients, 35 were in CR1, 10 in CR2, and three in relapse. The cumulative incidence of grade 3/4 aGVHD was 10.4% and that of extensive cGVHD was 28.4%. The CIR at three yr was 30.8% and that of NRM at three yr was 14.7%. At a median follow-up of 20.0 (range 2.5-124.2) months, the three-yr LFS was 54.4%. Children who received transplants during CR1 had a better LFS (65.7% vs. 26.0%, p = 0.008) and a lower relapse rate (19.8% vs. 56.7%, p = 0.014) compared to those during non-CR1. HID-SCT is feasible for HR T-ALL children, and survival outcomes are better when performed in CR1 compared to non-CR1. Prospective clinical trials would be needed to confirm that. |
URI | http://hdl.handle.net/20.500.11897/434439 |
ISSN | 1397-3142 |
DOI | 10.1111/petr.12704 |
Indexed | SCI(E) PubMed |
Appears in Collections: | 人民医院 |